2023 Year in Review





Badger Challenge advances state of the art cancer research and treatment to serve patients and families in Wisconsin by funding the brightest cancer minds, ideas, and technologies at the University of Wisconsin.



2023 TOTAL AMOUNT RAISED: \$1,034,012

\$1,200,000

\$1,000,000

\$800,000

\$600,000



\$3.6 MILLION RAISED SINCE 2016

2023



A MESSAGE FROM THE BADGER CHALLENGE TEAM

On behalf of the Badger Challenge team, we would like to extend our heartfelt gratitude for another year of overwhelming support. Witnessing the community come together to walk, run, and ride in honor of cancer survivors and those who have been affected by this disease is truly inspiring, and we are honored to be a part of it. This year has been especially remarkable, as it was a record breaking year in all regards – all thanks to you, our Badger Challenge Community. Your unwavering support has enabled us to move cancer research forward, and we are incredibly grateful.

Sincerely,

P. Praiai), luch

Dr. Paul Harari & Dr. Deric Wheeler





TOP FUNDRAISERS

INDIVIDUAL FUNDRAISERS

Dawn Walstad

Melissa Carr

Tom Foti

Arleen Wolek

Sean Grossberg

Jorie Enderby

Norman Patterson

Ann Lee

Victoria Gnadt

Kristen Grimes

TEAM FUNDRAISERS

Team FC

Team Wildflowers

DHO Physics Team

Fighting Against the Double C

CCC Tumornators

Team Oakwood

Bike2benefit George's Team

Team Triple E + Steve

Team Lola

Moran & Fraiser Family

CORPORATE TEAMS

Balance & Believe

Aldevron

RH Batterman

American Family Insurance

Ayres Associates

2023 Scholars



DR. TING FU COLORECTAL CANCER

Dr. Fu's laboratory is investigating the impact of particular microbial bile acids on intestinal epithelial cells. This research aims to facilitate earlier detection, enhance treatment strategies, and potentially prevent colorectal cancer. The ultimate goal is to alleviate the disease burden, improve survival rates, and enhance the overall quality of life for patients.



DR. ZACHARY MORRIS MELANOMA

Dr. Morris and his team are developing an innovative approach to enhance the effectiveness of therapy for specific types of melanoma that have metastasized to the spinal fluid. Currently, radiation therapy impacts the entire brain and spine, which has significant side effects. The team's proposed method directly delivers the treatment into the spinal fluid, precisely targeting tumor cells and minimizing impact on the surrounding brain, spinal cord, and bone.



DR. CARRI GLIDE-HURST MULTIPLE DISEASE SITES

Dr. Glide-Hurst and her research team are employing CT imaging to evaluate how positioning patients upright, versus laying down, affects the location of organs and tumors during the delivery of radiation therapy. This study is instrumental in establishing the foundation for the transition of upright radiation therapy from a research setting to practical clinical treatments.



DR. LIXIN RUI

Dr. Rui and his team are focused on addressing a mechanism that diminishes energy production in lymphoma cancer cells. Their research is geared towards formulating a targeted therapeutic approach with the objective of enhancing the long-term survival rates of B-cell lymphoma patients.



DR. ADAM KUCHNIA PANCREATIC CANCER

Dr. Kuchnia's team is dedicated to improving the early detection of cancer cachexia, or body wasting, through the utilization of clinical imaging tools and plasma biomarkers. This research aims to establish a diagnostic framework, addressing one of the most significant challenges in pancreatic cancer patients' care.



DR. WEIPING TANG HEAD & NECK CANCER

Dr. Tang and his team have created innovative small molecule drug candidates designed to activate the body's natural protein disposal system. This system is targeted to eliminate the protein AXL, crucial for both metastatic potential and drug resistance of head and neck cancer.



DR. JESSICA LANG OVARIAN CANCER

Dr. Lang's research is exploring novel methods to detect chemotherapy resistance in ovarian cancer before it becomes clinically evident. Her specific objective is to pinpoint predictive biomarkers or potential drug targets that could enhance outcomes for ovarian cancer patients in the future.



DR. MALINDA WEST BREAST CANCER

Dr. West and her team are investigating the impact of estrogen-blocking medications, commonly employed in the treatment of estrogen receptor-positive breast cancer, on the tumor microenvironment. Their research aims to understand how these medications can modify the microenvironment to facilitate immune system attacks on the tumor, ultimately promoting more effective tumor eradication.









POWERING RESEARCH. CURING CANCER.

SAVE THE DATE:

SEPTEMBER 22, 2024



BADGERCHALLENGE.ORG